Preliminary evidence supports circulating microRNAs as prognostic biomarkers for type 2 diabetes
Preliminary evidence supports circulating microRNAs as prognostic biomarkers for type 2 diabetes
复制标题
DOI：
10.1002/osp4.134
复制
发表时间：
2017-12-01
影响因子：
2.2
通讯作者：
Aouizerat, B. E.
中科院分区：
文献类型：
--
作者：
Flowers, E.;Kanaya, A. M.;Aouizerat, B. E.
背景循环microRNA是2型糖尿病发展的潜在预后生物标志物。然而，microRNA也与葡萄糖代谢受损（例如内皮细胞功能）的并发症有关。以前的研究没有评估循环microRNA的轨迹与空腹血糖随时间变化的轨迹以及对降低风险的行为干预的反应之间的关联。本研究进行了纵向评估的microRNA和空腹血糖和microRNA和行为风险降低interventions. MethodsMicroRNA（n = 353）之间的关系进行了测量，在子集（n = 10，n = 8）的参与者从以前完成的临床试验，研究行为风险降低干预措施。空腹血糖轨迹与45 microRNAs的变化超过12 months. ResultsAfter 3个月的体力活动和饮食干预与基线相比，13 microRNAs差异表达。7种microRNA（即miR-106 b、miR-20 b、miR-363、miR-486、miR-532、miR-92 a和miR-93）在两种分析之间被共同鉴定。这项研究的其他未来方向是区分microRNA是否是2型糖尿病风险的预后和/或诊断生物标志物以及对风险降低干预措施反应的预测生物标志物。
BackgroundCirculating microRNAs are emerging as potential prognostic biomarkers for the development of type 2 diabetes. However, microRNAs are also associated with complications from impaired glucose metabolism (e.g. endothelial cell function). Prior studies have not evaluated for associations between trajectories of circulating microRNAs with trajectories of fasting blood glucose over time and the responses to behavioral interventions to reduce risk. This study performed longitudinal assessment of microRNAs and fasting blood glucose and identified relationships between microRNAs and behavioral risk reduction interventions.MethodsMicroRNAs (n = 353) were measured in subsets (n = 10, n = 8) of participants from previously completed clinical trials that studied behavioral risk reduction interventions. Fasting blood glucose trajectories were associated with changes in 45 microRNAs over 12 months.ResultsFollowing a 3-month physical activity and dietary intervention compared with baseline, 13 microRNAs were differentially expressed. Seven microRNAs (i.e. miR-106b, miR-20b, miR-363, miR-486, miR-532, miR-92a and miR-93) were commonly identified between the two analyses.ConclusionsFurther studies are needed to determine which microRNAs are prognostic biomarkers of risk for type 2 diabetes versus consequences of impaired glucose metabolism. Additional future directions of this research are to differentiate whether microRNAs are prognostic and/or diagnostic biomarkers for risk for type 2 diabetes and predictive biomarkers of responses to risk reduction interventions.